Table 4 |
|||
|
Serious adverse events by treatment group |
|||
|
CQ (N = 79) |
SP (N = 77) |
SP – AS (N = 81) |
|
|
|
|||
|
Patients with any SAE, n (%) |
15 (19.0) |
10 (13.0) |
3 (3.7)‡ |
|
- Severe anaemia |
3 |
2 |
0 |
|
- Acute respiration infection |
2 |
2 |
3 |
|
- Seizure |
1 |
1 |
0 |
|
- Pyomyositis |
0 |
1 |
0 |
|
|
|||
|
(% calculated on the total number of patients). ‡ Comparison using Fisher's Exact test for SP-AS vs CQ (p = 0.002) and SP-AS vs SP (p = 0.043) |
|||
|
Nahum et al. Malaria Journal 2007 6:170 doi:10.1186/1475-2875-6-170 |
|||
